About Bio INX
Bio INX is a company based in Ghent (Belgium) founded in 2022 by Agnes Dobos, Aysu Arslan, and Jasper Van Hoorick. Bio INX has raised $500.63 thousand across 2 funding rounds. Bio INX offers products and services including Ready to use bio inks, Bio ink precursors, HYDROBIO INX U200, and DEGRAD INX U100. Bio INX operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, OxSyBio, Collplant and Precise Bio, among others.
- Headquarter Ghent, Belgium
- Founders Agnes Dobos, Aysu Arslan, Jasper Van Hoorick
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bio Inx
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$500.63 K (USD)
in 2 rounds
-
Latest Funding Round
$500.63 K (USD), Seed
Sep 19, 2022
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bio INX
Bio INX offers a comprehensive portfolio of products and services, including Ready to use bio inks, Bio ink precursors, HYDROBIO INX U200, and DEGRAD INX U100.
Bioinks for 3D printing in tissue applications
Precursors for custom bioprinting solutions
Resin for advanced cancer research models
Biodegradable resin for high-resolution printing
Funding Insights of Bio INX
Bio INX has successfully raised a total of $500.63K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $500.63 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Bio INX
Investment portfolio details for Bio INX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bio INX
Detailed financials for Bio INX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bio Inx Comparisons
Peer comparison for Bio INX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bio INX
Bio INX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, OxSyBio, Collplant and Precise Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Provider of 3D printing of tissue biomaterials for medical research and clinical applications
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
Developer of integrated 3D printing and tissue-engineering platform
|
|
| Locked | Locked | Locked |
4D bio-printer solutions for tissue regeneration are provided.
|
Detailed competitors of Bio INX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bio Inx
Complete news archive for Bio INX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bio INX
Bio INX was founded in 2022.
Bio INX is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Jasper Van Hoorick is the current CEO of Bio INX. They have also founded this company.
Bio INX is a funded company, having raised a total of $500.63K across 2 funding rounds to date.
Bio INX was established in 2022 in Ghent, Belgium, within the advanced materials sector. A range of 3D printing inks is offered, encompassing multiphoton lithography formulations, deposition-based variants, and solutions for digital light processing and stereolithography. These inks are designed with shear-thinning properties to facilitate flow during application and maintain shape post-deposition. Operations focus on supporting precision manufacturing in biomedical and engineering applications.
Bio INX's top competitors include Nuclera Nucleics, Xlife sciences and Collplant.
Bio INX offers Ready to use bio inks, Bio ink precursors, HYDROBIO INX U200, and DEGRAD INX U100.